Genomic Test Aims To Separate Current And Former Smokers Into Groups With Higher Or Lower Risks For Lung Cancer

FierceBiotech (5/19, Hale) reports Veracyte’s “Percepta genomic test aims to separate current and former smokers into groups with higher or lower risks for lung cancer, allowing those whose nodules are most likely benign to avoid additional procedures, wh...